A pproximately 500,000 people experience traumatic spinal cord injuries worldwide each year, and the development of potential therapies to reduce their morbidity and socioeconomic impact remains an urgent research priority [5] . Lifetime direct and indirect costs related to spinal cord injuries are estimated to exceed USD 3 million per person [12] , and annual total related healthcare costs in the United States alone are estimated to exceed more than USD 10 billion [4] .
Studies have suggested that methylprednisolone may minimize the secondary inflammatory damage that occurs after acute spinal cord injuries and in so doing, facilitate some measure of neurologic recovery, but the effectiveness of this treatment has been vigorously debated [5, 13] and its use has been linked to harms such as sepsis, infections, gastrointestinal hemorrhage, and even death [9] . In this Cochrane review, the pooled evidence from three randomized controlled trials failed to demonstrate a benefit attributable to methylprednisolone versus placebo for neurological recovery at 6 months or 1 year, but a subgroup analysis suggested that it might be associated with better recovery in patients who received treatment within 8 hours of their injuries. Evidence from one trial each failed to demonstrate an overall difference between high-dose and lowdose methylprednisolone, and between 24 hours and 48 hours of methylprednisolone.
Upon Closer Inspection
For the subgroup of patients who received treatment within eight hours, the evidence from three randomized controlled trials can be described as conflicting and inconsistent. Only one trial reported a neurologic benefit to A Note from the Editor-In-Chief: We are pleased to publish the next installment of Cochrane in CORR 1 , our partnership between CORR 1 , The Cochrane Collaboration 1 , and McMaster University's Evidence-Based Orthopaedics Group. In it, researchers from McMaster University and other institutions will provide expert perspective on an abstract originally published in The Cochrane Library that we think is especially important. [2, 3] , while another failed to do so at 6 months [14] and another failed to do so at 12 months [15] . The conclusions of this review were based on a pooled estimate that combined 6-month data with 1-year data and favored methylprednisolone, but the pooled effect using data at 1-year followup alone was not different from placebo.
Missing data threaten the validity of all meta-analyses, and readers should look for sensitivity analyses that test assumptions about the nature of the missing data because even plausible assumptions can change the magnitude or direction of the of the pooled effects [1] . For example, missing data might result from dropouts, losses to followup, nonadherence, or data entry errors, and each of these problems could potentially be related to patient outcomes in an important way. None of the three trials performed such an analysis, raising the question of whether in fact missing data could have had an important impact on the conclusions of the individual trials or even of the metaanalysis when those trials' data were pooled. The largest trial that evaluated methylprednisolone versus placebo (n = 333) had missing data for at least 11% of participants at six months and at least 14% at 1 year [2, 3] . To put this in perspective, Akl et al. identified a median of 6% losses to followup among 235 randomized controlled trials from top journals; up to one-third of these trials would have lost statistical significance if plausible assumptions about the nature of the missing data had been implemented [1] .
Take-Home Messages
Meta-analyses are powerful tools to support evidence-based care, but they require high methodological credibility in order to avoid misleading conclusions [6] . This Cochrane review did not assess confidence in the pooled estimates, and it did not consider whether small but statistically significant treatment effects were clinically meaningful. It also did not use multiple reviewers to perform the selection of studies, assessments of risk of bias, or the extraction of data, which raises the possibility that it was neither exhaustive nor reproducible. As such, this review does not permit strong inferences about the effectiveness of methylprednisolone in patients with acute spinal cord injuries. Until an updated review with more rigorous methodology is available, clinicians, researchers, and other evidence users should exercise caution when interpreting the results and applying them to patient care.
Metaregression, a technique of metaanalysis that combines individual participant-level data from existing prospective observational or randomized trials, could assist in further clarifying the role of methylprednisolone for enhancing neurological recovery in these severely injured patients by acknowledging the influence of strong confounding variables [7, 17] . Additional randomized controlled trials would also be helpful, but the high costs and clinical burden inherent to prospective analyses of steroid use in spinal cord injury may limit their feasibility.
Although many clinicians still report a belief in the effectiveness of methylprednisolone or a fear of litigation if they do not administer it, utilization has decreased in many countries over the last decade [10, 16] . The 2013 guidelines of the American Association of Neurological Surgeons and Congress of Neurological Surgeons recommended against the routine administration of methylprednisolone for acute traumatic spinal cord injuries [18] , and several other groups have previously contributed to similar statements [8, 11] .
